Chemotherapy for Cerebral Gliomas: Current Status and Future Perspectives

Glioma ◽  
1991 ◽  
pp. 217-232
Author(s):  
D. G. T. Thomas
Keyword(s):  
Current Status ◽  
Future Perspectives ◽  
Cerebral Gliomas

Role of Pharmacogenomics in Antiepileptic Drug Therapy: Current Status and Future Perspectives

2018 ◽  
Vol 23 (37) ◽  
pp. 5760-5765 ◽  
Author(s):  
Antonio Gambardella ◽  
Angelo Labate ◽  
Laura Mumoli ◽  
Iscia Lopes-Cendes ◽  
Fernando Cendes
Keyword(s):  
Drug Therapy ◽  
Antiepileptic Drug ◽  
Current Status ◽  
Future Perspectives ◽  
Antiepileptic Drug Therapy

Radio-localization of Non-Palpable Breast Lesions Under Ultrasonographic Guidance: Current Status and Future Perspectives

2017 ◽  
Vol 10 (3) ◽  
Author(s):  
Giulia Anna Follacchio ◽  
Francesco Monteleone ◽  
Maria Letizia Meggiorini ◽  
Maria Paola Nusiner ◽  
Carlo De Felice ◽  
...  
Keyword(s):  
Current Status ◽  
Breast Lesions ◽  
Future Perspectives ◽  
Radio Localization ◽  
Palpable Breast ◽  
Ultrasonographic Guidance

Immunotherapy in Gastric Carcinoma: Current Status and Future Perspectives

2015 ◽  
Vol 2 (2) ◽  
pp. 91-99 ◽  
Author(s):  
Lionel Kankeu Fonkoua ◽  
Nelson S Yee
Keyword(s):  
Gastric Carcinoma ◽  
Current Status ◽  
Future Perspectives

scholarly journals Artificial intelligence and colonoscopy: Current status and future perspectives

2019 ◽  
Vol 31 (4) ◽  
pp. 363-371 ◽  
Author(s):  
Shin‐ei Kudo ◽  
Yuichi Mori ◽  
Masashi Misawa ◽  
Kenichi Takeda ◽  
Toyoki Kudo ◽  
...  
Keyword(s):  
Artificial Intelligence ◽  
Current Status ◽  
Future Perspectives

scholarly journals Molluscs and echinoderms aquaculture: biological aspects, current status, technical progress and future perspectives for the most promising species in Italy

2012 ◽  
Vol 11 (4) ◽  
pp. e72 ◽  
Author(s):  
Giuliana Parisi ◽  
Gerardo Centoducati ◽  
Laura Gasco ◽  
Pier Paolo Gatta ◽  
Vittorio M. Moretti ◽  
...  
Keyword(s):  
Technical Progress ◽  
Current Status ◽  
Future Perspectives ◽  
Biological Aspects

scholarly journals Clinical Candidates Targeting the ATR–CHK1–WEE1 Axis in Cancer

Cancers ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 795
Author(s):  
Lukas Gorecki ◽  
Martin Andrs ◽  
Jan Korabecny
Keyword(s):  
Cell Cycle ◽  
Cancer Cells ◽  
Molecular Mechanisms ◽  
Patient Survival ◽  
Current Status ◽  
Future Perspectives ◽  
Phase Ii Trials ◽  
Anticancer Treatment ◽  
Positive Outlook ◽  
Insight Into

Selective killing of cancer cells while sparing healthy ones is the principle of the perfect cancer treatment and the primary aim of many oncologists, molecular biologists, and medicinal chemists. To achieve this goal, it is crucial to understand the molecular mechanisms that distinguish cancer cells from healthy ones. Accordingly, several clinical candidates that use particular mutations in cell-cycle progressions have been developed to kill cancer cells. As the majority of cancer cells have defects in G1 control, targeting the subsequent intra‑S or G2/M checkpoints has also been extensively pursued. This review focuses on clinical candidates that target the kinases involved in intra‑S and G2/M checkpoints, namely, ATR, CHK1, and WEE1 inhibitors. It provides insight into their current status and future perspectives for anticancer treatment. Overall, even though CHK1 inhibitors are still far from clinical establishment, promising accomplishments with ATR and WEE1 inhibitors in phase II trials present a positive outlook for patient survival.

Sign in / Sign up

Export Citation Format

Share Document